<DOC>
	<DOCNO>NCT01328496</DOCNO>
	<brief_summary>In study , participant high-risk hematologic malignancy undergo hematopoietic cell transplantation ( HCT ) , suitable human leukocyte antigen ( HLA ) -matched related/sibling donor ( MSD ) , match unrelated donor ( MURD ) killer-immunoglobulin receptor ( KIR ) ligand mismatch haploidentical donor identify , receive umbilical cord blood transplantation ( UCBT ) use myeloablative preparative regimen . The preparative regimen include fludarabine ( 75 mg/m2 ) , fractionate total body irradiation ( TBI ) ( 10.0 Gy ) , cyclophosphamide ( 120mg/kg ) mesna . Fludarabine give day 25 mg/m2 three day day -10 day -8 , TBI give twice day 150 cGy four day day -7 day -4 , cyclophosphamide give day 60mg/kg two day day -3 day -2 . Post-transplantation immunosuppression cyclosporine MMF begin day -3 . Cord Blood infusion occur day 0 G-CSF start day +1 .</brief_summary>
	<brief_title>Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen</brief_title>
	<detailed_description>The primary objective estimate event-free survival ( EFS ) one-year post-transplant research participant high-risk hematologic malignancy undergo hematopoietic cell transplantation ( HCT ) use single unit umbilical cord blood ( UCB ) . Secondary objective : - Describe clinical outcome patient undergo double unit UCBT . - Estimate incidence severity acute chronic graft versus host disease ( GVHD ) patient enrol research arm . - Estimate incidence time neutrophil platelet engraftment among patient enrol research arm . - Estimate incidence transplant relate mortality ( TRM ) transplant relate morbidity first 100 day transplantation among patient enrol research Exploratory Objectives : - Assess relationship pre-transplant minimal residual disease ( MRD ) transplant outcome . - Record immune reconstitution parameter , include chimerism analysis , quantitative lymphocyte subset , T cell receptor excision circle ( TREC ) spectratyping . Immunophenotyping functional assay T , B NK cell lymphocytes also evaluate . - Evaluate determinant engraftment .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<criteria>Age le equal 21 year old . Has partially HLAmatched single double UCB product Highrisk hematologic malignancy . High risk ALL CR1 , ALL High risk CR2 , ALL CR3 subsequent . AML high risk CR1 , AML CR2 subsequent AML first relapse &lt; 25 % blast BM Therapy relate AML , prior malignancy CR &gt; 12mo MDS , primary secondary NK cell , biphenotypic , undifferentiated leukemia CR1 subsequent . CML accelerate phase , chronic phase persistent molecular positivity intolerance tyrosine kinase inhibitor . Hodgkin lymphoma CR2 subsequent failure prior autologous HCT , unable mobilize stem cell autologous HCT . NonHodgkin lymphoma CR2 subsequent failure prior autologous HCT , unable mobilize stem cell autologous HCT . JMML All patient evidence CNS leukemia must treat CNS CR eligible study . Patient must fulfill pretransplant evaluation : Cardiac shorten fraction ≥ 26 % . Creatinine clearance ≥ 70 ml/min/1.73m2 . Forced vital capacity ( FVC ) ≥ 50 % predict value pulse oximetry ≥ 92 % room air . Karnofsky ( ≥ 16 year ) Lansky ( &lt; 16 year ) performance score ≥ 70 Bilirubin ≤ 2.5 mg/dL . Alanine aminotransferase ( ALT ) ≤ 5 time upper limit normal age . Aspartate aminotransferase ( AST ) ≤ 5 time upper limit normal age . Patient suitable MSD , volunteer MURD , KIR mismatch haploidentical donor available necessary time stem cell donation . Patient active malignancy one HCT indicate . Patient prior allogeneic HCT Patient autologous HCT within previous 12 month . Patient pregnant confirm positive serum urine pregnancy test within 14 day prior enrollment . Patient lactate Patient Down Syndrome Patient current uncontrolled bacterial , fungal , viral infection per judgment PI .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hematologic Malignancies</keyword>
	<keyword>Umbilical Cord Blood transplantation</keyword>
	<keyword>Hematopoietic Cell Transplantation</keyword>
</DOC>